Our analysis indicates that reducing lipoprotein-associated phospholipase A2 (Lp-PLA2) via statin therapy can prevent ATIN, while an increase in Lp-PLA2 protects against tubulointerstitial nephritis (TIN). This evidence concerns the gene PLA2G7 and interstitial nephritis.